Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: Olinvacimab With Pembrolizumab in Patients With mTNBC [Phase 2]
A Phase 2 study evaluating Olinvacimab in combination with pembrolizumab for metastatic triple-negative breast cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer [Phase 3]
This Phase 3 trial assesses atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic PD-L1-positive triple-negative …
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. [Phase 1]
This is a Phase 1 dose-escalation and expansion study evaluating intratumoral ONM-501 alone and in combination with cemiplimab in patients w…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. [Phase 2]
A Phase 2 trial evaluating sacituzumab govitecan as first-line therapy in adults with advanced untreated triple-negative breast cancer; the …
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer [Phase 2]
A Phase 2 trial of pembrolizumab in combination with mifepristone for advanced HER2-negative breast cancer has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC [Phase 3]
Phase 3 trial evaluating capivasertib plus paclitaxel as first-line treatment for locally advanced or metastatic triple-negative breast canc…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) [NA]
Clinical trial NCT06349512 is evaluating 68Ga-FAPI-46 PET/CT imaging to predict histological response in triple-negative breast cancer and i…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer [Phase 3]
A Phase 3 clinical trial (SHR-A1811) for PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer is curren…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
An ongoing clinical trial at Fudan University investigates how psychological state influences immunotherapy response in triple-negative brea…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
This ClinicalTrials.gov entry describes a prospective registry evaluating an antibody-drug conjugate as first- and second-line therapy for b…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer [NA]
This ClinicalTrials.gov study assesses MRI screening for brain metastases in patients with triple-negative or HER2-positive stage II/III bre…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: FMT in Triple Negative Breast Cancer Guided by ctDNA [Phase 1, Phase 2]
A clinical trial is exploring fecal microbiota transplantation for triple-negative breast cancer, guided by ctDNA, in Phase 1/Phase 2, which…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer [Phase 3]
A Phase 3 trial is evaluating standard chemotherapy plus moxifloxacin as first-line treatment for metastatic triple-negative breast cancer a…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors [Phase 2]
Phase 2 clinical trial of TJ004309 in combination with atezolizumab (TECENTRIQ) for ovarian cancer and selected solid tumors has completed e…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) [Phase 1]
A Phase 1 clinical trial evaluating preoperative lenvatinib plus pembrolizumab in early-stage triple-negative breast cancer is currently rec…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) [Phase 2]
This clinical trial update describes a Phase 2 study evaluating temozolomide alone or in combination with olaparib for triple-negative breas…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating SGN-LIV1A in combination with pembrolizumab for locally advanced or metastatic triple-negative breast…
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer [Phase 2]
This is a Phase 2 clinical trial evaluating whether hypofractionated radiotherapy should be given before or after breast surgery in non-meta…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab [Phase 3]
A Phase 3 trial evaluating adjuvant avelumab for high-risk triple-negative breast cancer has completed.
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating olaparib for recurrent and metastatic triple-negative breast cancer with BRCA1/2 unmutated or BRCA1 promoter methyl…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer [NA]
A nutrition intervention trial for women undergoing active treatment for triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-12-10Clinical Trial Update: Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI). [EARLY_Phase 1]
An early-phase pilot study evaluating whether contrast-enhanced ultrasound can predict treatment response to chemotherapy plus immune checkp…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer [Phase 3]
A Phase 3 clinical trial comparing SKB264 injection against investigator-selected regimens for locally advanced, recurrent, or metastatic tr…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer [Phase 2]
The TREND-02 trial update describes a Phase II exploratory neoadjuvant study of sacituzumab govitecan plus tislelizumab in early triple-nega…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy [Phase 1]
A Phase 1 study evaluating the safety and preliminary efficacy of combining rucaparib with radiation in triple-negative breast cancer patien…